Hypera SA (HYPMY) recently announced a dividend of $0.06 per share, payable on a date yet to be confirmed, with the ex-dividend date set for October 5, 2023. As investors eagerly anticipate this ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Hypera SA (HYPMY) recently announced a dividend of $0.02 per share, payable on a date yet to be confirmed, with the ex-dividend date set for 2024-03-22. As investors look forward to this upcoming ...

SAO PAULO (Reuters) - Brazil's Hypera Pharma said on Monday that it has signed a contract to buy a portfolio of 18 products from Japan's Takeda Pharmaceutical Co for $825 million. Shares in Hypera ...

SAO PAULO, May 26 (Reuters) - Brazilian drugmaker Hypera Pharma said its co-controlling shareholder will reimburse the company after an internal probe found "irregular payments" made by former ...

Brazil's leading pharmaceutical company Hypera SA believes it can sustain market share gains it had this year and deliver on guidance for 2022, CEO Breno Oliveira told analysts in a conference call on ...

SAO PAULO, Oct 24 (Reuters) - The board of directors of Brazil's pharmaceutical company Hypera (HYPE3.SA), opens new tab has unanimously decided to reject rival EMS's offer to merge, it said on ...

Brazilian pharmaceutical company Hypera has discussed a takeover offer from rival company NC Group, the owner of EMS SA, but talks are not currently active, one source with knowledge of the matter ...

Good morning, ladies and gentlemen, and welcome to Hypera Pharma's Conference Call where we will discuss the earnings for the third quarter of 2025. We have with us Mr. Breno Oliveira, CEO; and Mr.

Hypera Pharma, along with all Rimini Street clients, benefits from the Company’s flexible, premium-level enterprise software support model, including its industry-leading Service Level Agreement (SLA) ...